Compounding Pharmacy

The source of choice for compounding and dispensing of pharmaceutical preparations for pharmacists, technicians and students.

pharmacy preparation

Popular posts from this blog

Facts about SOVALDI Therapy

Image
SOVALDI  It is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%. Here is some facts about SOVALDI that pharmacist must know: Active constituent of SOVALDI is sofosbuvir 400 mg. SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection. SOVALDI not recommended using alone for Chronic Hepatitis C patients. The dose of SOVALDI is 400 mg once daily, to be taken regardless of food. Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa. Genotype-2 HCV treated for 12 weeks with SOVALDI +ribavirin. Genotype-3 HCV treated for 24 weeks with SOVALDI +ribavirin. Genotype-4 treated for 12 weeks with SOVALDI +Peginterferon a...
Read more

Pharmacy Examining Board of Canada Questions & Answers

Image
Overview Q1 What is the Pharmacy Examining Board of Canada? The Pharmacy Examining Board of Canada ( PEBC ) is the national certification body for the pharmacy profession in Canada. PEBC is a non-profit organization with more than 40 years of experience in assessing the qualifications and competence of candidates for licensing by pharmacy provincial regulatory authorities. Established by Special Act of Parliament on December 21,1963, PEBC functions as an arms-length national examining board for pharmacists seeking entry-to-practice licensure in Canada. Q2 What is the purpose of the PEBC?
Read more

15 Facts about HARVONI the recent Hepatitis C from Gilead

Image
HARVONI   It is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on 10  October  2014, as first Hepatitis C drug combination, that used alone without need to ribavirin or peginterferon alfa, as in case of SOVALDI. Harvoni 15 facts: Used for treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. HARVONI dose is one tablet to be taken once daily regardless of food. Treatment duration varies according to the case and presence of liver cirrhosis. In naive cirrhotic or not, and in experienced non cirrhotic, they treated for 12 weeks. In naive non-cirrhotic patient with PCR < 6million IU/ml, treatment may reduced to 8 weeks. In experienced cirrhotic patients the treatment extends for 24 weeks. Experienced patients who have failed to treat with other medications. HARVONI used alone without the need to peginterferon al...
Read more